Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CoLucid Pharmaceuticals Inc.

This article was originally published in Start Up

Executive Summary

CoLucid Pharmaceuticals starts out with an in-licensed migraine drug from Eli Lilly, one of a new class of molecules known as neurally acting anti-migraine agents. The phase II drug has demonstrated equal efficacy to triptans in the control of migraine symptoms without triptans' risk of cardiovascular side effects. CoLucid is also developing a wake-promotion drug using technology licensed from Sention.

You may also be interested in...

Start-Up Previews (09/2008)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Bone Building Start-Ups," features profiles of OsteoCorp, OsteoGeneX, Pradama, and Therosteon. Plus these Start-Ups Across Health Care: Aileron Therapeutics, Cohera Medical, CoLucid Pharmaceuticlas and Endogun Medical Systems.

Homology Medicines Inc.

Gene editing has made a great many headlines of late, and one could be forgiven for thinking the field was saturated, but Homology Medicines Inc. offers something new. Its platform relies on a different mechanism, known as homologous recombination, and the start-up's management team believes the approach can get around some of the potential limitations found in other gene-editing technologies.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts